Abstract: A testing system can perform scalability testing on a target system, including automatically identifying a performance bottleneck component of the target system when the target system includes multiple components. The testing system can specify a target load of a specified component of the target system. The testing system can provide a simulated request to the target system and measure performance of the target system. Based on the measurement, the testing system can determine a scaling factor. The testing system can scale up the simulated request by the scaling factor, and determine whether one or more components of the target system have reached full capacity. The testing system can then adjust the scaling factor and the simulated request, until the testing system identifies a component of the target system that is a performance bottleneck of the target system when a specific number of requests are provided.

Abstract: Described herein are a method and apparatus including calculating an aggregate peak total traffic demand for all overlapping access points in an interference range, comparing the aggregate peak total traffic demand to a threshold, rejecting a requested new quality of service traffic stream responsive to results of the comparison, calculating a peak total traffic demand for each overlapping access point in the interference range if the requested new quality of service traffic stream is admissible responsive to results of the comparison, comparing the peak total traffic demand for each overlapping access point in the interference range, if the requested new quality of service traffic stream is admissible, to the threshold and one of accepting the requested new quality of service traffic stream and rejecting the requested new quality of service traffic stream responsive to results of the second comparison.

Abstract: A device includes a substrate with a device region surrounded by an isolation region, in which the device region includes edge portions along a width of the device region and a central portion. The device further includes a gate layer disposed on the substrate over the device region, in which the gate layer includes a graded thickness in which the gate layer at edge portions of the device region has a thickness TE that is different from a thickness TC at the central portion of the device region.

Abstract: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

Abstract: Methods for the diagnosis of inflammatory bowel diseases and the identification of agents useful in the treatment of such diseases based upon the agent's effect on reducing Pim-2 expression.

Abstract: A bladed tool includes a handle and a blade with a surface-engaging edge and a blade-retaining shank. The handle includes an elongated handle body having longitudinally opposed body front and rear ends, and at least one side wall extending between the body front and rear ends. The side wall defines an outer surface configured for gripping by a user and an inner surface that defines an interior access channel extending from an access opening in the body rear end toward a forward channel wall located to the rear of the body front end. Situated between the body front end and the forward channel wall is a handle core that defines a shank-retaining slot extending between a forward slot-opening in the body front end and a rearward slot-opening in the forward channel wall. The shank extends rearwardly through the shank-retaining slot such that a protruding shank portion extends to the rear of the forward channel wall.

Abstract: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

Abstract: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

Abstract: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

Abstract: A catalyst system for use with an internal combustion engine to provide emissions reductions under lean and stoichiometric operating conditions. The catalyst system comprises a first catalyst comprised of a newly developed Perovskite-based formulation having an ABO3 crystal structure designed to bring the precious metal and NOx trapping elements close together. The first catalyst acts primarily to maximize the reduction of emissions under lean operating conditions. The catalyst system also comprises a second catalyst comprised of precious metals which acts primarily to maximize the reduction of emissions under stoichiometric conditions.

Abstract: A lean NOx trap composition. The lean NOx trap composition utilizes ruthenium in place of higher cost metals such as platinum. The lean NOx trap composition provides high NOx storage efficiency and high NOx conversion efficiency when incorporated in a lean NOx trap. A method of removing harmful gases using the lean NOx trap composition is also described.

Abstract: Methods for the diagnosis of inflammatory bowel diseases and the identification of agents useful in the treatment of such diseases based upon the agent's effect on reducing Pim-2 expression.

Abstract: A catalyst system for use with an internal combustion engine to provide emissions reductions under lean and stoichiometric operating conditions. The catalyst system comprises a first catalyst comprised of a newly developed Perovskite-based formulation having an ABO3 crystal structure designed to bring the precious metal and NOx trapping elements close together. The first catalyst acts primarily to maximize the reduction of emissions under lean operating conditions. The catalyst system also comprises a second catalyst comprised of precious metals which acts primarily to maximize the reduction of emissions under stoichiometric conditions.

Abstract: A lean NOx trap composition. The lean NOx trap composition utilizes ruthenium in place of higher cost metals such as platinum. The lean NOx trap composition provides high NOx storage efficiency and high NOx conversion efficiency when incorporated in a lean NOx trap. A method of removing harmful gases using the lean NOx trap composition is also described.

Abstract: A light assembly is provided having a lens assembly that splits the function of a near field lens into two components, thereby permitting a manufacturable lens that achieves the desired beam size and intensity. At the same time, increased flexibility and control over the beam spread characteristics is achieved. The first component is an inner lens, while the second component may be a reflector or a second lens.

Abstract: A bifunctional LED headlamp for a vehicle is disclosed, wherein at least one of a shield, a lens, a reflector, and an LED are movable to facilitate use of the headlamp in both a low beam mode and a high beam mode.

Abstract: A method of determining whether a subject is suffering from or at risk for developing inflammatory diseases by determining the level of HM74 and/or HM74A in tissue damage. Also disclosed are a method of identifying a compound for treating inflammatory diseases, a method of treating inflammatory diseases, and a pharmaceutical composition or a packaged product for treating inflammatory diseases.

Abstract: A catalyst system to provide emission reductions under lean and stoichiometric conditions. The catalyst system comprises a forward catalyst having a first cerium-free zone including oxides of aluminum, alkali metals and alkaline earth metals and precious metals and a second zone with a lower loading of precious metals, oxides of aluminum, alkali metals or alkaline earth metals. This forward catalyst stores NOx emissions under lean conditions for subsequent reduction and converts HC, CO and NOx during stoichiometric operation. The second downstream catalyst includes precious metals, reduces emissions under stoichiometric conditions, and stores any residual NOx emitted from the first catalyst for subsequent reduction. In another embodiment, a forward catalyst has top and bottom layers designed to reduce emissions under lean conditions. In this embodiment, a second downstream catalyst is used to reduce emissions under stoichiometric conditions.